Presenter's Information

Seung-Jung Park, MD

Country Korea (Republic of)
Specialty Interventional Cardiologist
  1. 15 Years' Journey of AMC TAVR
  2. The PREVENT Trial: Confirmative RCT of Preventive PCI of Vulnerable Plaque
  3. Case 1. Practical Issue of Left Main & Multi-Vessel PCI: Make it Simple!
  4. Revascularization for Left Main Disease: Updated Data, Global Guidelines and Beyond
  5. LM PCI: Make-It-Simple!
  6. What Really Matters in LM Bifurcation PCI: Concept or Technique?
  7. 10 Year's Journey of AMC TAVR
  8. PREVENT Trial
  9. Functionally Insignificant Vulnerable Plaque; Treat or Not?
  10. Non-LM Bifurcation PCI in 2023: Don't Touch Small Side Branch, Evolving Changes in AMC Practice
  11. Insight from All Data for Triple Vessel Disease
  12. Don't Touch Small Side Branch! Concept Changes After ISCHEMIA Study
  13. My Approach to Multi-vessel Disease - Master\'s Skill Secret
  14. Non-LM Bifurcation Revascularization 2022: Guidelines and Concept Change
  15. The Last 10 Year TAVR Path and Achievement of ASAN MEDICAL CENTER
  16. Updated Techniques and Concepts 2021 for Complex Left Main PCI
  17. Why Mismatching? FFR vs. Angiographic %DS
  18. Minimalist TAVR: AMC Experience
  19. What Is the Practical Approach to LM/MVD Revascularization? - Make It Simple!!
  20. PREVENT: Physiology and Imaging for PREVENTing Future Events
  21. [Debate: Should All CTOs Be Opened?] Cons
  22. MAIN COMPARE: 10-Year Follow-up
  23. What Is the Benefit of CTO PCI?: Insights from the DECISION CTO
  24. Physiology-Guidance: Synergetic Hybrid Approach for Complex PCI
  25. 10-year Outcomes of MAIN-COMPARE Study: Main and Key Substudies
  26. [Featured Lecture] LM-PCI: New Techniques, Concept, and Insights from the LM Pioneer
  27. PCI vs CABG for Left Main and Multivessel Disease
  28. Integrated Use of FFR and IVUS in LM PCI
  29. TAVR in Asia, Korea, and AMC
  30. PREVENT Trial: Update and Interesting Cases
  31. The Lesson from DECISION-CTO Trial
  32. All the Data from IRIS-FFR Registry
  33. To Treat or Not to Treat for Gray Zone FFR(0.76-0.80)
  34. [Debate: Should All CTOs Be Opened?] Con
  35. Top 10 Tips on Left Main PCI
  36. Keynote Lecture on Left Main PCI: Expert\'s Concept and Technique
  37. Future Perspective of Bioresorbable Vascular Scaffolds (ABSORBII, ABSORBIII, AIDA-AMC Registry) : Is It a Crisis or a Chance to Move Forward?
  38. Can BRS Stabilize Vulnerable Plaque?: PREVENT
  39. [Debate: Left Main Disease - How to Treat in Contemporary Era?] LM Is No Longer Surgical Disease.
  40. How To Manage Grey Zone FFR?: Data from IRIS FFR Registry
  41. Impact of Complete Revascularization for Multivessel PCI
  42. PREVENT Trial: Update and Insight from Plaque Imaging
  43. Impact of Complete Revascularization for MVD PCI
  44. Why PCI ? - Rationale for PCI / - Patient & Lesion Selection
  45. Is It a Matter of Technique or Concept?: Left Main and Bifurcation PCI
  46. From STABLE to PREVENT
  47. FFR and Clinical Outcomes: Evidence Has Never Been Stronger
  48. Left Main PCI: The Simpler, The Better
  49. Case 1: Left Main Disease
  50. Left Main & Bifurcation PCI: Is It a Matter of Technique or Concept?
  51. Relationship Between FFR and Clinical Outcome: Data from IRIS-FFR Registry
  52. Can We Prevent Events of Vulnerable Plaques?: From STABLE to PREVENT
  53. FFR: How to Change Our Practice?
  54. Integrated Approach for LM PCI Using IVUS and FFR
  55. What Happened in Deferred Lesion: Insight from IRIS-FFR Registry
  56. Please Keep It: IVUS-Guidance for LM Stenting
  57. Left Main Disease Is Not Surgical Treatment Any More: Data-Supported 2015
  58. Fate of Deferred Lesion: Insight from Prospective IRIS-FFR Registry
  59. Plaque Stabilization and Preemptive BVS: From STABLE to PREVENT
  60. How to Treat? - Functionally Insignificant Vulnerable Plaque: STABLE and PREVENT
  61. Trial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease
  62. Can We Prevent Future Event?: PREVENT Trial - Design and Rationale
  63. Impact of FFR
  64. IVUS Is Enough!
  65. How Good FFR Guided in Real Practice from Asan PCI and Multivessel Registry & IRIS-FFR Registry
  66. Can We Prevent DEFER Lesion Event? PREVENT Trial - Design and Rationale
  67. Asian Multicenter Registry
  68. FFR Guided Clinical Practice of Left Main PCI
  69. [FFR Use at CathLab: More & Better] FFR-guided PCI in Routine Practice: Lessons from the AMC Experience
  70. Temporal Trends and Outcomes of Contemporary LM Treatment: From the Asan Left Main Registry
  71. Either FFR or IVUS Is Acceptable, but Choose Your Cutoff Values Wisely!
  72. 15-year Temporal Change of LM Revascularization: Lesson from Asan Main Registry
  73. Do You Want to Treat?: Functionally Insignificant Vulnerable Plaque - No, I Don\'t. We Can\'t Predict Fate of Vulnerable Plaque.
  74. Meta-analysis of LM PCI: PCI Using DES vs. CABG
  75. How Good FFR Guided in Real Practice: Data from Asan PCI and Multivessel Registry
  76. IVUS-MLA and FFR
  77. Coronary Angiography versus FFR: Why Mismatches
  78. [Functionally Insignificant, Vulnerable Plaque: Do You Want to Treat?] No, I Don't
  79. TAVI in Korea: How to Avoid Conduction Disturbance..
  80. PCI vs CABG from BARI to SYNTAX: Is the Game over?
  81. Functional Evaluation Is Necessary !
  82. Impact of Functional Angioplasty in Our Real Practice!
  83. Impact of Functional Angioplasty to Current Practice: Trends in Clinical Outcomes of PCI with Drug Eluting Stents
  84. Featured Lecture: The Fate of PCI for Multi-Vessel Disease in the Era of COURAGE, SYNTAX, FAME, and FREEDOM
  85. Now, Do the IVUS-MLA Criteria Need to Be Adjusted ?
  86. When and How We Utilize Imaging and Functional Information in LM Stenting
  87. Clinical Outcomes from RCTs and Registries
  88. Why Visual-functional Mismatch? New Insight from Computational Simulation and Imaging Data
  89. New Frontiers in Left Main Intervention; Functional Angioplasty and New Optimizing Criteria
  90. Why Visual-functional Mismatches?
  91. FFR Guided and IVUS Supported Functional Angioplasty
  92. Device Positioning Is Crucial.
  93. Functional PCI for LM Stenosis: IVUS and FFR Guided
  94. [Debate: Can We Safely Defer PCI Just Based on FFR>0.80?] Yes, Already Proven.
  95. Functional Angioplasty - Insight from FFR and IVUS
  96. Why Visual-Functional Mismatches?
  97. Invited Case Presentation & Focus Review: FFR Guided Spot Stenting for Tandem Lesion PCI
  98. Discrepancy between Anatomic vs. Functional Parameters (IVUS vs. FFR)
  99. It's Not Enough !
  100. Long and Tandem Lesion Intervention: FFR Guided Spot Stenting
  101. Pre-COMBAT: LM Disease Revascularization - PCI vs. CABG Randomization Study
  102. Is Angiography Enough To Guide LMT PCI? - 'Functional Approach Should Be Considered!'
  103. Left Main PCI: Where We Are? Where We Are Going?
  104. Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease
  105. Anatomic vs. Functional Assessment of Coronary Artery Stenosis: Can IVUS-Derived Minimal Lumen Area Predict FFR < 0.8?
  106. Case Based Learning
  107. Paradigm Shift to Functional Angioplasty: FFR Guided Decision Making, IVUS Guided Optimization
  108. PCI in Unprotected Left Main Disease (MAIN-COMPARE, SYNTAX, and Several Registries)
  109. Xience V in Real Life
  110. Duration of Dual Antiplatelet Therapy in DES
  111. Insight into LM PCI from Main-COMPARE, SYNTAX LM, and Registries
  112. Coronary Intervention
  113. Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation
  114. DECISION CTO_New Horizon in CTO Treatment; Randomized Study Proposal
  115. Comparison of Sirolimus- and Paclitaxel-Eluting Stents vs Zotarolimus-Eluting Stents in Real World Practice: The ZEST Randomized Controlled Trial
  116. Future Clinical Study for Nobori Stent in Korea
  117. The Impact of Diabetes in the DES Long-Term Outcome
  118. Prognostic Influence of DM on Long-Term Clinical Outcomes and Stent Thrombosis Following DES Implantation in Asian: AMC Experience
  119. Can SYNTAX Score Be Feasible to Predict Outcomes of LM Revascularization?: Application to MAIN-COMPARE Registry
  120. Can Carotid Artery Stenting Before CABG Reduce Perioperative Stroke ?
  121. Tailores Approach with DES for Long Coronary Lesions
  122. \"ZEST\" Trial
  123. PCI vs CABG in Left Main Disease: Main Registry Update
  124. Impact of Diabetes on Long-Term Outcomes of Drug-Eluting Stents in Asian Patients
  125. Long-Term Evaluation of DES vs. BMS; 10-Year Experience from Single Center Registry
  126. How Can We Optimize Good Result in the Long Coronary Lesion ?
  127. Left Main Trifurcation Intervention
  128. LM Intervention Is Still an Available Option Despite Late Stent Thrombosis?
  129. VH-IVUS: Matched and Mismatched
  130. Nobori Stent, Update
  131. VH Experience in Real World: Asan Medical Center
  132. How to Treat - Unprotected Left Main Disease
  133. LM Bifurcation Intervention Guideline for COMBAT
  134. Safety and Efficacy of Cypher on Complex Lesion
  135. LM stenting -Cypher
  136. Drug Eluting Stent: Real World Experience(AMC Registry Study)
  137. Long Cypher Multicenter Registry Study
  138. Aggressive Colesterol Lowering Therapy after PCI(Percutaneous Coronary Intervention)
  139. Long-DES: Study presented in TCT 2004
  140. Treatment of In-Stent Restenosis : Drug Eluting Stent versus Brachytherapy
  141. Is bypass surgery needed for elderly patients with left main coronary artery disease? - CON l
  142. Safety and Effectiveness of Sirolimus Eluting Stent for Left Main Coronary Artery Stenosis
  143. Long Cypher?Multicenter Registry Study in Korea
  144. Bail-out stenting for Unprotected Left Main Coronary Artery Dissection during Catheter-Based Procedure
  145. Cypher vs. Taxus ; Taxus vs. Cypher - Is there something different ?
  146. Primary Stenting for Unprotected Left Main Coronary Artery Stenosis during AMI
  147. Percutaneous Mitral Valvuloplasty: State of Art
  148. Coronary Perforation of Proximal LAD after Debulking for LMCA Ostial Stenosis, Treated with PTEE-covered JoStent
  149. Why Polymer Coated Paclitaxel Stents
  150. Percutaneous Intervention of Unprotected left main Disease
  151. Technical Feasibility, Safety, and Clinical Outcome of Stenting of Unprotected Left Main Coronary Artery Bifurcation Narrowing Equipment Overview of DCA Device Percutaneous Intervention of Unprotected Left Main Disease
  152. PCI for Chroic Total Occlusion
  153. Drug-Eluting Stent
  154. Left Main Ostial Stenosis after Aortic Valve Replacement
  155. Percutaneous Intervention of Unprotected Left Main Ostial and Shaft Disease
Conference Slides
Category